Ownership and insider activity for Zai Lab Limited (ZLAB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders.
Price
| Price | $24.67 |
| Market Cap | $2.8B |
| Exchange | NASDAQ |
| Country | CN |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-19 | Chen Yajing | S-Sale | 260 | $7K |
| 2026-08-14 | Chen Yajing | M-Exempt | 1,250 | |
| 2026-08-14 | Chen Yajing | F-InKind | 427 | $11K |
| 2026-08-14 | Chen Yajing | M-Exempt | 1,250 | |
| 2026-08-12 | Lis William | S-Sale | 8,506 | $213K |
| 2026-08-11 | Chen Yajing | S-Sale | 619 | $15K |
| 2026-07-01 | GAYNOR RICHARD | P-Purchase | 1,736 | $33K |
| 2026-07-02 | Du Ying | M-Exempt | 11,048 | |
| 2026-07-01 | Du Ying | M-Exempt | 18,000 | |
| 2026-07-02 | Du Ying | F-InKind | 4,348 | $83K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $83.9M | $229.7M | $63.0M | $75.9M | $442.1M | $964.1M | $1.01B | $790.2M | $449.7M | $679.6M |
| Short-term Investments | 0 | 0 | $200.3M | $200.0M | $744.7M | $445.0M | 0 | $16.3M | $330.0M | $10.0M |
| Receivables | 0 | 0 | $90000 | $3.8M | $5.2M | $54.8M | $48.6M | $65.3M | $89.4M | $106.1M |
| Inventory | 0 | 0 | $3822 | $6.0M | $13.1M | $19.0M | $31.6M | $44.8M | $39.9M | $74.7M |
| Total Current Assets | $84.1M | $230.6M | $269.1M | $292.5M | $1.22B | $1.50B | $1.12B | $939.6M | $1.05B | $1.02B |
| Property, Plant & Equipment | $2.7M | $12.0M | $20.8M | $36.9M | $47.1M | $58.3M | $78.8M | $68.7M | $69.5M | $66.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $7000 | $20089 | $321566 | $8.8M | $9.4M | $9.7M | $8.4M | $16.5M | $58.9M | $76.1M |
| Total Assets | $88.9M | $249.6M | $302.0M | $355.2M | $1.30B | $1.61B | $1.22B | $1.04B | $1.19B | $1.17B |
| Accounts Payable | $523337 | $9.0M | $37.4M | $22.7M | $62.6M | $126.2M | $66.0M | $113.0M | $100.9M | $141.6M |
| Short-term Debt | 0 | 0 | $3.6M | $6.5M | 0 | 0 | 0 | 0 | $131.7M | $204.5M |
| Total Current Liabilities | $5.2M | $12.1M | $48.8M | $46.6M | $98.0M | $192.9M | $139.8M | $203.1M | $299.4M | $416.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $13.4M |
| Total Liabilities | $140.5M | $14.5M | $50.9M | $60.5M | $128.3M | $230.0M | $174.5M | $240.2M | $344.9M | $456.9M |
| Retained Earnings | -$60.2M | -$110.6M | -$249.6M | -$444.7M | -$713.6M | -$1.42B | -$1.86B | -$2.20B | -$2.45B | -$2.63B |
| Total Equity | -$51.6M | $235.2M | $251.1M | $294.7M | $1.17B | $1.38B | $1.05B | $796.1M | $840.9M | $715.5M |
| Total Debt | 0 | 0 | $3.6M | $21.8M | $18.6M | $15.5M | $20.4M | $15.2M | $153.5M | $224.3M |
| Net Debt | -$83.9M | -$229.7M | -$259.7M | -$254.2M | -$1.17B | -$1.39B | -$988.1M | -$791.3M | -$626.2M | -$465.3M |
| Working Capital | $78.9M | $218.5M | $220.3M | $245.8M | $1.12B | $1.31B | $984.5M | $736.5M | $751.1M | $603.1M |
Financial Health
| Debt / Equity | 0.31 |
| Current Ratio | 2.45 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -0.22 |
Profitability
| Return on Equity | -24.53% |
| Return on Invested Capital | -22.74% |
| Return on Assets | -14.97% |
| Gross Margin | 58.47% |
| Operating Margin | -48.59% |
| Net Margin | -38.15% |
Related companies: AAPG · APGE · CDTX · CNTA · IDYA · IRON · LEGN
Explore sector: Healthcare · Biotechnology
More sections of ZLAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks